Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03912883 Active, not recruiting - Prostate Cancer Clinical Trials

Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting

TAPG
Start date: October 12, 1999
Phase:
Study type: Observational

The Trans-Atlantic Prostate Group (TAPG) was established to examine the hypothesis that through a detailed retrospective analysis of outcome in a group of men with clinically localised prostate cancer at diagnosis, variables such as biological, pathological and clinical markers, could be identified that might accurately predict the prognosis of clinically localised prostate cancer. In 1999, the TAPG group initiated the "Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting" study, referred to as the TAPG study. It is a retrospective population-based tissue sample study in men diagnosed with localised prostate cancer 1990-2006, inclusively. Initially the cohort comprised men diagnosed with prostate cancer with transurethral resection of the prostate (TURP) and needle biopsies 1990-1996, but was expanded from 2005 to include men diagnosed with prostate cancer 1990 - 2006. Data was collected from six regional cancer registries and eligibility was confirmed via hospital sites, which sent the relevant tissue samples to the TAPG Central Coordinating Office (CCO). Selection of eligible patients for the study completed in 2010. Since this year the TAPG CCO has been collecting cancer registration and mortality updates on the cohort members from regional cancer registries.

NCT ID: NCT03887091 Active, not recruiting - Prostate Cancer Clinical Trials

Personal Web Page In Clinical Trial Participant Education

Start date: July 21, 2014
Phase: N/A
Study type: Interventional

This research study is evaluating the effectiveness of video and web-based communication in clinical research compared to standard practices.

NCT ID: NCT03770351 Active, not recruiting - Prostate Cancer Clinical Trials

Early Prostate Cancer: Predicting Treatment Response

Start date: January 2017
Phase:
Study type: Observational [Patient Registry]

This study will replicate/validate the risk prediction model developed for the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study in a more diverse patient population to assess generalizability of the model as well as evaluate the relative contribution of the Decipher Prostate Cancer Test and ProstateNext Test from Ambry Genetics, to the risk prediction model for estimating treatment outcomes, and thereby improve personalization of treatment options.

NCT ID: NCT03768349 Active, not recruiting - Prostate Cancer Clinical Trials

Gallium-68 PSMA-11 and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer

Start date: January 3, 2019
Phase: Phase 2
Study type: Interventional

Imaging and staging of prostate cancer is critical for surgical and treatment planning. In this protocol we will image patients with suspected metastatic prostate cancer using 11C-Choline PET and Gallium-68 labeled HBED-CC PSMA (more commonly called 68Ga-PSMA-11) in order to demonstrate their utility in detecting prostate cancer.

NCT ID: NCT03692104 Active, not recruiting - Prostate Cancer Clinical Trials

US-CT Fusion for Post Implant Dosimetry

Start date: November 3, 2017
Phase:
Study type: Observational

Post implant dosimetry is an essential part of quality assurance after permanent seed prostate brachytherapy. CT imaging is the standard of assessment but due to contouring uncertainties, MR-CT fusion is preferred. This is not always available due to financial restrictions. This study explores the possibility of post implant US-CT fusion to improve contouring accuracy and potentially replace the use of MR-CT fusion.

NCT ID: NCT03692000 Active, not recruiting - Prostate Cancer Clinical Trials

Designing a Digital Tool to Support Healthy Lifestyle in Men With Prostate Cancer

Emil2
Start date: February 23, 2018
Phase:
Study type: Observational

The emil project aims to design, develop, implement and evaluate a digital service to support a healthy lifestyle among men with prostate cancer. In this second study, men with a history of prostate cancer are invited to participate in the scoping and design of a digital platform, through three iterations of workshops and individual interviews, which includes prototyping and other ideation processes. Finally, the men with a history of prostate cancer will be involved in the usability testing of the design, to ensure a platform fit for use by the intended users.

NCT ID: NCT03630926 Active, not recruiting - Prostate Cancer Clinical Trials

Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.

VPAC
Start date: October 16, 2018
Phase:
Study type: Observational

This is a double-blind, study to evaluate the performance of NV-VPAC1 PCa Urine Diagnostic Test in three distinct populations being treated at the Intermountain Urology Clinic. The first population (positive control) is comprised of men with biopsy-confirmed PCa who are scheduled for prostatectomy. The second population (negative control) is comprised of men with benign prostatic hypertrophy (BPH) who are scheduled for transurethral resection of the prostate (TURP). The third population (negative control) is comprised of men or women with bladder/kidney stones who are scheduled for a cystoscopy.

NCT ID: NCT03543670 Active, not recruiting - Prostate Cancer Clinical Trials

Evaluation of Oncoxin-Viusid® in Prostate Cancer

Start date: September 16, 2017
Phase: Phase 2
Study type: Interventional

A not randomized clinical survey was done in 25 pacients with histological diagnosis confirmed of a prostatic adenocarcinoma and hardy in hormonotherapy at the Calixto Garcia Hospital in Habana (2016-2018). Researches had as identifying goal the efecctiveness study of Oncoxin-Viusid® nutritional supplement as a support to convencional treatment. The patient were treated with habitual doses of Docetacel and 75 mg per day of supplement during and fiften day after the quimiotherapy. The rest of numbers and severety of adverse reactions were determined as well as its influences on life quality when this co-therapy is performed, the evaluation of progresion spare survival and the porcentage of recurrences.

NCT ID: NCT03480074 Active, not recruiting - Prostate Cancer Clinical Trials

Staple vs. Suture in Robotic Prostatectomy

Start date: March 1, 2015
Phase: N/A
Study type: Interventional

The purpose of the study is to compare the results of three standard of care surgical methods [stapling versus selective suture ligation (cut, then sew) versus single suture ligation (sew, then cut) of the dorsal venous complex (DVC)] during robotic prostate surgery to see which is better for the patient's recovery.

NCT ID: NCT03477591 Active, not recruiting - Prostate Cancer Clinical Trials

Evaluating the Impact of Evidence-based Information About PSA Testing on Prostate Cancer Screening Decisions

Start date: October 1, 2018
Phase: N/A
Study type: Interventional

Patient decision aids are tools that help guide individuals through a healthcare-related decision making process. They help users combine evidence-based information and recommendations by a health care provider with their personal needs, values and preferences. Through this project, Dr. Dobbins and her research team will explore whether the use of patient decision aids with high-quality and user-friendly summaries of research evidence, or summaries of research evidence alone, help to improve the quality of decision making by men facing prostate cancer screening decisions.